查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1954193

抗药性金黄色葡萄球菌(MRSA) 市场分析及预测（至 2035 年）：按类型、产品、服务、技术、应用、设备、最终用户、流程和解决方案划分

Methicillin-Resistant Staphylococcus Aureus (MRSA) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, End User, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 329 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计抗药性金黄色葡萄球菌(MRSA) 市场规模将从 2024 年的 51 亿美元成长至 2034 年的 76 亿美元，复合年增长率约为 4.1%。 MRSA 市场涵盖 MRSA感染疾病的诊断工具、治疗方法和预防措施的开发和分销。市场成长的驱动因素包括 MRSA 感染率的上升、快速诊断技术的进步以及对有效抗药性金黄色葡萄球菌治疗的需求。主要趋势包括新型抗生素的出现、疫苗的研发以及医疗机构感染控制通讯协定的加强。

由于诊断技术的进步和治疗方法的创新，抗药性金黄色葡萄球菌(MRSA) 市场预计将迎来显着成长。诊断领域，尤其是快速诊断检测，表现良好，这主要得益于对及时准确检测 MRSA 的需求。分子诊断工具因其更高的灵敏度和特异性而日益重要，在 MRSA 疫情控制中发挥至关重要的作用。治疗领域也紧随其后，新型抗生素和联合治疗正成为 MRSA感染疾病控制的关键组成部分。随着传统治疗方法面临抗药性挑战，对新型抗生素的需求不断增长。包括卫生用品和消毒解决方案在内的感染控制领域也呈现强劲成长，凸显了预防措施的重要性。此外，医院感染控制通讯协定也越来越多地采用先进的灭菌和消毒技术。旨在开发创新解决方案以应对日益严重的 MRSA 威胁的策略联盟和研究倡议进一步巩固了市场地位。

市场区隔
类型 院内获得性抗甲氧西林金黄色葡萄球菌（MRSA）、社区型抗甲氧西林金黄色葡萄球菌（MRSA）
产品 抗生素、消毒剂、防腐剂和创伤护理产品
服务 诊断、咨询和治疗服务
科技 聚合酵素链锁反应（PCR）、微阵列、免疫检测
适用的 医院、诊所、居家医疗机构、实验室
医疗设备 诊断和治疗设备
最终用户 医疗保健机构、研究机构和製药公司
流程 筛检和监测
解决方案 感染控制、抗菌药物管理计划

抗药性金黄色葡萄球菌(MRSA) 市场正经历市场份额、定价策略和产品创新的动态变化。主要企业正致力于开发新型治疗方法以应对日益严重的抗药性问题。这造就了竞争激烈的市场格局，定价策略对于维持市场地位至关重要。各公司正迅速推出承诺提高疗效并减少副作用的新产品。策略重点在于拓展产品系列，以满足未被满足的需求并改善患者预后。地域扩张和策略联盟对于获取市场份额也至关重要。 MRSA 市场的竞争基准研究显示，该市场格局高度分散，众多公司竞相争夺主导。监管影响显着，严格的指导方针规范新治疗方法的开发和核准。该市场的特点是研发活动十分活跃，各公司大力投资创新以获得竞争优势。北美和欧洲在法规结构处于主导地位，影响全球市场动态。对抗菌药物管理和降低抗药性策略的重视正在推动市场发展，带来成长机会和创新。

主要趋势和驱动因素：

由于感染率上升和人们对抗生素抗药性的认识不断提高，耐甲氧西林金黄色葡萄球菌（MRSA）市场正在成长。关键趋势包括新型抗生素和快速诊断工具的研发，这些对于有效控制MRSA感染疾病至关重要。此外，严格的监管指南和不断加强的病患安全措施也提高了医疗机构感染预防措施的重要性。市场驱动因素包括MRSA感染疾病在全球日益普遍，需要有效的治疗方案。现有抗生素的局限性以及对更具针对性治疗方法的需求进一步推动了对先进治疗方法的需求。此外，政府和私营部门对研发的投资正在加速该领域的创新。在MRSA负担沉重的新兴市场，扩大医疗基础设施存在着机会。专注于提供价格合理且易于获得的治疗方案的公司有望占据可观的市场份额。此外，製药公司与研究机构合作开发下一代抗生素和诊断解决方案，预计将推动MRSA市场的持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 本院内感染抗甲氧西林金黄色葡萄球菌
    • 社区型抗甲氧西林金黄色葡萄球菌
  • 市场规模及预测：依产品划分
    • 抗生素
    • 抗菌剂
    • 消毒剂
    • 创伤护理产品
  • 市场规模及预测：依服务划分
    • 诊断服务
    • 咨询服务
    • 治疗服务
  • 市场规模及预测：依技术划分
    • 聚合酵素链锁反应（PCR）
    • 微阵列
    • 免疫检测
  • 市场规模及预测：依应用领域划分
    • 医院
    • 诊所
    • 居家医疗环境
    • 研究所
  • 市场规模及预测：依设备划分
    • 诊断设备
    • 治疗设备
  • 市场规模及预测：依最终用户划分
    • 医疗保健提供者
    • 研究所
    • 製药公司
  • 市场规模及预测：依製程划分
    • 筛检
    • 监测
  • 市场规模及预测：按解决方案划分
    • 感染控制
    • 抗菌药物管理计划

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 其他亚太地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Melinta Therapeutics
  • Paratek Pharmaceuticals
  • Nabriva Therapeutics
  • Cempra
  • Achaogen
  • Motif Bio
  • Basilea Pharmaceutica
  • Tetraphase Pharmaceuticals
  • Iterum Therapeutics
  • Aridis Pharmaceuticals
  • Debiopharm Group
  • Spero Therapeutics
  • Enanta Pharmaceuticals
  • Venatorx Pharmaceuticals
  • Forge Therapeutics
  • Wockhardt
  • Polyphor
  • Shionogi
  • Biocidium
  • Micu Rx Pharmaceuticals

第九章：关于我们

简介目录
Product Code: GIS26118

Methicillin-Resistant Staphylococcus Aureus (MRSA) Market is anticipated to expand from $5.1 billion in 2024 to $7.6 billion by 2034, growing at a CAGR of approximately 4.1%. The Methicillin-Resistant Staphylococcus Aureus (MRSA) Market encompasses the development and distribution of diagnostic tools, treatments, and preventive measures for MRSA infections. This market is driven by the increasing prevalence of MRSA, advancements in rapid diagnostic technologies, and the need for effective antibiotic therapies. Key trends include the rise of novel antibiotics, vaccine development, and enhanced infection control protocols in healthcare settings.

The Methicillin-Resistant Staphylococcus Aureus (MRSA) Market is poised for significant growth, propelled by advancements in diagnostic technologies and therapeutic innovations. The diagnostic segment, particularly rapid diagnostic tests, leads in performance, driven by the need for timely and accurate detection of MRSA. Molecular diagnostic tools are gaining prominence, offering enhanced sensitivity and specificity, which are critical in managing MRSA outbreaks. The therapeutic segment follows closely, with novel antibiotics and combination therapies emerging as vital components in combating MRSA infections. The demand for newer antibiotics is rising, as traditional treatments face resistance challenges. The infection control segment, encompassing hygiene products and decontamination solutions, is also witnessing robust growth, underscoring the importance of preventive measures. Furthermore, hospital-acquired infection control protocols are increasingly incorporating advanced sterilization and disinfection technologies. The market is further bolstered by strategic collaborations and research initiatives aimed at developing innovative solutions to address the growing MRSA threat.

Market Segmentation
TypeHospital-Acquired MRSA, Community-Acquired MRSA
ProductAntibiotics, Antiseptics, Disinfectants, Wound Care Products
ServicesDiagnostic Services, Consultation Services, Treatment Services
TechnologyPolymerase Chain Reaction (PCR), Microarray, Immunoassay
ApplicationHospitals, Clinics, Home Care Settings, Research Laboratories
DeviceDiagnostic Devices, Therapeutic Devices
End UserHealthcare Providers, Research Institutes, Pharmaceutical Companies
ProcessScreening, Surveillance
SolutionsInfection Control, Antimicrobial Stewardship

The Methicillin-Resistant Staphylococcus Aureus (MRSA) market is witnessing a dynamic shift in market share, pricing strategies, and product innovation. Key players are focusing on developing novel treatments to address the growing resistance issues. This has led to a competitive landscape where pricing strategies are crucial for maintaining market presence. Companies are launching new products that promise enhanced efficacy and reduced side effects. The strategic emphasis is on expanding product portfolios to cater to unmet medical needs and improve patient outcomes. Geographical expansion and strategic partnerships are also pivotal in capturing market share. Competition benchmarking in the MRSA market reveals a highly fragmented landscape with numerous players vying for dominance. Regulatory influences play a significant role, as stringent guidelines shape the development and approval of new treatments. The market is characterized by intense R&D activities, with firms investing heavily in innovation to gain a competitive edge. North America and Europe lead in regulatory frameworks, impacting global market dynamics. The focus on antibiotic stewardship and resistance mitigation strategies is driving market evolution, presenting opportunities for growth and innovation.

Geographical Overview:

The Methicillin-Resistant Staphylococcus Aureus (MRSA) market is witnessing varied growth patterns across different regions. North America remains a dominant player, benefiting from advanced healthcare infrastructure and significant R&D investments. The region's proactive approach towards infection control and robust healthcare policies further bolsters the market's expansion. Europe is experiencing steady growth, driven by heightened awareness and stringent healthcare regulations. The region's commitment to combating antibiotic resistance is fostering a conducive environment for MRSA market development. In Asia Pacific, burgeoning healthcare infrastructure and rising public health initiatives are propelling market growth. Countries like India and China are emerging as pivotal players, investing heavily in healthcare advancements. Latin America shows promising potential, with increased focus on healthcare improvements and infection control measures. The Middle East & Africa are gradually recognizing the importance of addressing MRSA, with countries in these regions beginning to invest in healthcare solutions to combat antibiotic-resistant infections.

The MRSA market is increasingly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, reliance on imported raw materials for antibiotics faces tariff-induced cost pressures, prompting strategic investments in local pharmaceutical R&D. China's focus on strengthening its domestic healthcare infrastructure is accelerated by trade tensions, fostering innovation in MRSA treatments. Taiwan's robust biopharmaceutical sector remains crucial but is vulnerable to geopolitical volatility. The global MRSA market is expanding, driven by rising infection rates and healthcare demands. By 2035, market evolution will hinge on supply chain resilience, regional collaborations, and technological advancements. Additionally, Middle East conflicts may indirectly affect pharmaceutical supply chains by influencing energy prices, thereby impacting production and distribution costs globally.

Key Trends and Drivers:

The MRSA market is experiencing growth due to rising infection rates and increased awareness of antibiotic resistance. Key trends include the development of novel antibiotics and rapid diagnostic tools, which are essential in managing MRSA infections effectively. Additionally, there is a growing emphasis on infection prevention measures in healthcare settings, driven by stringent regulatory guidelines and patient safety initiatives. Drivers of the market include the increasing prevalence of MRSA infections globally, which necessitates effective treatment solutions. The demand for advanced therapeutics is further fueled by the limitations of existing antibiotics and the need for more targeted therapies. Furthermore, government and private sector investments in research and development are accelerating innovation in this field. Opportunities lie in the expansion of healthcare infrastructure in emerging markets, where the burden of MRSA is significant. Companies focusing on affordable and accessible treatment options can capture substantial market share. Additionally, partnerships between pharmaceutical companies and research institutions are fostering the development of next-generation antibiotics and diagnostic solutions, positioning the MRSA market for sustained growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hospital-Acquired MRSA
    • 4.1.2 Community-Acquired MRSA
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Antibiotics
    • 4.2.2 Antiseptics
    • 4.2.3 Disinfectants
    • 4.2.4 Wound Care Products
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Consultation Services
    • 4.3.3 Treatment Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Polymerase Chain Reaction (PCR)
    • 4.4.2 Microarray
    • 4.4.3 Immunoassay
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Home Care Settings
    • 4.5.4 Research Laboratories
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Diagnostic Devices
    • 4.6.2 Therapeutic Devices
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Healthcare Providers
    • 4.7.2 Research Institutes
    • 4.7.3 Pharmaceutical Companies
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Screening
    • 4.8.2 Surveillance
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Infection Control
    • 4.9.2 Antimicrobial Stewardship

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Melinta Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Paratek Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Nabriva Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cempra
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Achaogen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Motif Bio
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Basilea Pharmaceutica
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Tetraphase Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iterum Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Aridis Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Debiopharm Group
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Spero Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Enanta Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Venatorx Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Forge Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Wockhardt
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Polyphor
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Shionogi
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Biocidium
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Micu Rx Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us